Glancy Binkow & Goldberg LLP Encourages Investors of Achillion Pharmaceuticals, Inc. with Losses of $250,000 or More to Contact

  Glancy Binkow & Goldberg LLP Encourages Investors of Achillion
  Pharmaceuticals, Inc. with Losses of $250,000 or More to Contact the Firm

Business Wire

LOS ANGELES -- October 9, 2013

Glancy Binkow & Goldberg LLP announces that it is investigating potential
claims on behalf of investors of Achillion Pharmaceuticals, Inc. (“Achillion”
or the “Company”) (NASDAQ:ACHN) concerning possible violations of federal
securities laws. Investors with losses of $250,000 or more are encouraged to
contact the firm for more information.

Please contact us at (212) 682-5340, Toll-Free at (888) 773-9224, or at
shareholders@glancylaw.com to discuss this matter. If you inquire by email
please include your mailing address, telephone number and number of shares
purchased.

Achillion is a biopharmaceutical company engaged in the discovery, development
and commercialization of anti-infective drug therapies in the United States
and internationally. The Company focuses on the development of antiviral
therapies for the treatment of chronic hepatitis C viral (HCV) infection. One
of the Company’s lead clinical-stage drug candidates is sovaprevir – a
treatment for chronic HCV infection – designed for use in combination with
other therapeutic products with complementary mechanisms of action. The
investigation is related to allegations that the Company misrepresented or
failed to disclose that sovaprevir did not interact well with other drugs
commonly used to treat hepatitis or patients infected with both hepatitis and
human immunodeficiency virus (HIV).

On July 1, 2013, Achillion disclosed that the Food and Drug Administration
instituted a clinical hold on sovaprevir after elevations in liver enzymes
were noted in a “Phase I healthy subject drug-drug interaction study
evaluating the effects of concomitant administration of sovaprevir with
ritonavir-boosted atazanavir.” Subsequently, on September 27, 2013, the
Company disclosed that the FDA had continued its clinical hold on sovaprevir
after the agency concluded that “removal of the clinical hold is not
warranted.”

If you purchased Achillion shares between April 21, 2012 and September 27,
2013, if you have information or would like to learn more about these claims
or have any questions concerning this announcement or your rights or interests
with respect to these matters, please contact Michael Goldberg, Esquire, of
Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles,
California 90067, Toll-Free at (888) 773-9224, or contact Gregory Linkh,
Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920,
New York, New York 10168, at (212) 682-5340, by e-mail to
shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com.
If you inquire by email, please include your mailing address, telephone number
and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

Contact:

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg
(888) 773-9224
or
Glancy Binkow & Goldberg LLP, New York, NY
Gregory Linkh
(212) 682-5340
shareholders@glancylaw.com
www.glancylaw.com